DIE MESSE „COSMETIC 360" GIBT DAS DIESJÄHRIGE THEMA BEKANNT: „REGENERATIONEN"

This reads more like a roadmap for where category premium can come from than a near-term P&L event. The investable signal is that prestige beauty is trying to defend pricing power by shifting the conversation from branding to science-heavy, regenerative claims; that favors incumbents with real formulation R&D and regulatory credibility, and it hurts commoditized brands that compete mainly on marketing spend. The second-order winner is likely the enablement layer — specialty ingredients, biotech platforms, and contract manufacturers — because they capture the incremental innovation budget without bearing full consumer demand risk.

For LRLCY, the value is mostly narrative reinforcement: it supports a premium multiple if management can translate the theme into measurable mix improvement in skincare and adjacent wellness categories. But conference language has low earnings elasticity unless it leads to launches, patents, or distribution wins; otherwise the market will fade it after a short-lived sentiment pop. The relevant horizon is 1-3 months for any event-driven re-rating, and 6-18 months for actual margin and share gains.

Contrarian take: the market may be underestimating how quickly "regeneration" gets commoditized once Asian and indie brands copy it at lower price points. The real competitive risk is not a lack of innovation spend, but that innovation becomes table stakes and the margin accrues to the fastest formulators rather than the biggest brands. Falsifiers are simple: if LRLCY shows no acceleration in premium skin-care organic growth or if EL stabilizes China exposure and launches credible biotech-led products, the relative trade case weakens materially.